Current Trends In Biologics-Related Inter Partes Reviews

By John Molenda and Richard Praseuth (July 20, 2017, 12:28 PM EDT) -- Inter partes review is increasingly becoming the method of choice for challenging patents directed to blockbuster biopharmaceuticals and methods of their manufacture. Examples include challenges to patents relating to aging biologics such as Rituxan[1] and Humira,[2] next-generation biologics such as Kadcyla,[3] and methods of manufacturing biologics.[4]...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!